| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hyperemesis Gravidarum | D006939 | 2 associated lipids |
| Typhoid Fever | D014435 | 2 associated lipids |
| Chromoblastomycosis | D002862 | 2 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Diphtheria | D004165 | 2 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
| Empyema, Pleural | D016724 | 2 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Mastoiditis | D008417 | 2 associated lipids |
| Periodontal Abscess | D010508 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Giacometti A et al. | In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. | 2005 | Antimicrob. Agents Chemother. | pmid:16127075 |
| Peric M et al. | Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. | 2003 | Antimicrob. Agents Chemother. | pmid:12604536 |
| Watanabe K et al. | Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. | 2004 | Antimicrob. Agents Chemother. | pmid:15561829 |
| Kim JM et al. | Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. | 2004 | Antimicrob. Agents Chemother. | pmid:15561865 |
| Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
| Roblin PM et al. | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. | 2010 | Antimicrob. Agents Chemother. | pmid:20038627 |
| Hammerschlag MR et al. | In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. | 1992 | Antimicrob. Agents Chemother. | pmid:1324650 |
| Nagashima A et al. | Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. | 2016 | Antimicrob. Agents Chemother. | pmid:27550358 |
| Perronne C et al. | Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. | 1990 | Antimicrob. Agents Chemother. | pmid:2171421 |
| Goldstein EJ et al. | Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. | 1999 | Antimicrob. Agents Chemother. | pmid:10543769 |
| Loreto ES et al. | New insights into the in vitro susceptibility of Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25223997 |
| Chan GP et al. | Clinical trial of clarithromycin for lepromatous leprosy. | 1994 | Antimicrob. Agents Chemother. | pmid:8203847 |
| Onyeji CO et al. | Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages. | 1994 | Antimicrob. Agents Chemother. | pmid:8203849 |
| Clark C et al. | In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:12183253 |
| Hunt Gerardo S et al. | Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. | 1996 | Antimicrob. Agents Chemother. | pmid:8891154 |
| Lemaire S et al. | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. | 2009 | Antimicrob. Agents Chemother. | pmid:19564365 |
| Steele-Moore L et al. | In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. | 1999 | Antimicrob. Agents Chemother. | pmid:10383373 |
| Kuo CC et al. | In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8913488 |
| Diacon AH et al. | Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. | 2012 | Antimicrob. Agents Chemother. | pmid:22391540 |
| Rouse MS et al. | Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. | 1997 | Antimicrob. Agents Chemother. | pmid:9257739 |
| Cynamon MH et al. | Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. | 2000 | Antimicrob. Agents Chemother. | pmid:10991883 |
| Fong IW et al. | Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. | 2002 | Antimicrob. Agents Chemother. | pmid:12121899 |
| Pryjma M et al. | Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. | 2017 | Antimicrob. Agents Chemother. | pmid:28874379 |
| Bolhuis MS et al. | Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. | 2013 | Antimicrob. Agents Chemother. | pmid:23689722 |
| Horgen L et al. | Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. | 1998 | Antimicrob. Agents Chemother. | pmid:9797242 |
| Conte JE et al. | Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. | 1995 | Antimicrob. Agents Chemother. | pmid:7726492 |
| Seyama S et al. | Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. | 2016 | Antimicrob. Agents Chemother. | pmid:26953210 |
| Berry V et al. | Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. | 1998 | Antimicrob. Agents Chemother. | pmid:9835514 |
| Chu SY et al. | Absolute bioavailability of clarithromycin after oral administration in humans. | 1992 | Antimicrob. Agents Chemother. | pmid:1387301 |
| Yajko DM et al. | Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. | 1992 | Antimicrob. Agents Chemother. | pmid:1387302 |
| Zhanel GG et al. | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. | 2008 | Antimicrob. Agents Chemother. | pmid:18285482 |
| Truffot-Pernot C et al. | Clarithromycin is inactive against Mycobacterium tuberculosis. | 1995 | Antimicrob. Agents Chemother. | pmid:8593032 |
| Naik S and Ruck R | In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. | 1989 | Antimicrob. Agents Chemother. | pmid:2817858 |
| Collins LA et al. | Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 | Antimicrob. Agents Chemother. | pmid:9527783 |
| Phillips RO et al. | Reply to "compliance with antimicrobial therapy for buruli ulcer". | 2014 | Antimicrob. Agents Chemother. | pmid:25225343 |
| Klis S et al. | Compliance with antimicrobial therapy for buruli ulcer. | 2014 | Antimicrob. Agents Chemother. | pmid:25225342 |
| Bermudez LE et al. | Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. | 1998 | Antimicrob. Agents Chemother. | pmid:9449283 |
| Portaels F et al. | In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9687409 |
| Heifets LB et al. | Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium. | 1992 | Antimicrob. Agents Chemother. | pmid:1416852 |
| Brown BA et al. | Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. | 1992 | Antimicrob. Agents Chemother. | pmid:1416891 |
| Biehle J and Cavalieri SJ | In vitro susceptibility of Mycobacterium kansasii to clarithromycin. | 1992 | Antimicrob. Agents Chemother. | pmid:1416897 |
| Chu SY et al. | Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. | 1992 | Antimicrob. Agents Chemother. | pmid:1489187 |
| Finch R et al. | Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. | 2002 | Antimicrob. Agents Chemother. | pmid:12019085 |
| Mougari F et al. | Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. | 2017 | Antimicrob. Agents Chemother. | pmid:27799212 |
| Kutlin A et al. | Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. | 2002 | Antimicrob. Agents Chemother. | pmid:11796350 |
| Nash KA | Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. | 2001 | Antimicrob. Agents Chemother. | pmid:11353601 |
| Alffenaar JW et al. | Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. | 2010 | Antimicrob. Agents Chemother. | pmid:20585115 |
| Hoffman HL et al. | Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. | 2003 | Antimicrob. Agents Chemother. | pmid:12543686 |
| Ji B et al. | Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. | 1994 | Antimicrob. Agents Chemother. | pmid:7872741 |
| Skinner PS et al. | A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. | 1994 | Antimicrob. Agents Chemother. | pmid:7872747 |
| Valero G et al. | Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection. | 1994 | Antimicrob. Agents Chemother. | pmid:7872769 |
| Aoki D et al. | Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production. | Anticancer Res. | pmid:15816530 | |
| Ohara T et al. | Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. | 2004 Nov-Dec | Anticancer Res. | pmid:15736403 |
| Gintovt EA | [Use of clarithromycin in the treatment of atopic dermatitis complicated by staphylococcal infection]. | 2004 | Antibiot. Khimioter. | pmid:15164520 |
| Vasil'ev IuV and Zvenigorodskaia LA | [Fromilide (clarithromycin) in eradication of Helicobacter pylori in patients with duodenal ulcer]. | 2002 | Antibiot. Khimioter. | pmid:12365323 |
| Iakovlev EA et al. | [Present stage of chemotherapy and chemoprophylaxis of rickettsiosis and Q fever]. | 2011 | Antibiot. Khimioter. | pmid:22856156 |
| Iakovlev VP | [New semisynthetic macrolides. Clarithromycin--its importance in the current therapy of bacterial infections]. | 1999 | Antibiot. Khimioter. | pmid:10635418 |
| Evdokimova AG et al. | [New approaches to therapy of Helicobacterpylori infection (by the materials of the Maastricht Consensus-IV, Florence, 2010)]. | 2013 | Antibiot. Khimioter. | pmid:24640139 |
| Iakovlev VP et al. | [Macrolide antibiotic clarithromycin (Klabax) in treatment of community-acquired respiratory tract infections]. | 2000 | Antibiot. Khimioter. | pmid:11210297 |
| Shcherbakov PL | [Clarithromycin in eradication therapy of helicobacter infections in children]. | 2001 | Antibiot. Khimioter. | pmid:11871315 |
| Sazykin IuO et al. | [Clarithromycin and tumor chemotherapy]. | 2000 | Antibiot. Khimioter. | pmid:11210301 |
| Iutanova NS | [Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia]. | 2004 | Antibiot. Khimioter. | pmid:15344392 |
| Budanov SV and Vasil'ev AN | [Clarithromycin: specific features of antimicrobial spectrum and clinical use]. | 2004 | Antibiot. Khimioter. | pmid:15285409 |
| Guchev IA et al. | [Evaluation of clarithromycin efficacy in the treatment of community-acquired pneumonia on the basis of the Binax NOW test results (a prospective open trial)]. | 2002 | Antibiot. Khimioter. | pmid:12619516 |
| Hiramatsu M et al. | Risk factors that affect the surgical outcome in the management of focal bronchiectasis in a developed country. | 2012 | Ann. Thorac. Surg. | pmid:22119119 |
| Fan X et al. | Lung perfusion with clarithromycin ameliorates lung function after cardiopulmonary bypass. | 2006 | Ann. Thorac. Surg. | pmid:16488691 |
| Nelson KG et al. | Results of operation in Mycobacterium avium-intracellulare lung disease. | 1998 | Ann. Thorac. Surg. | pmid:9725364 |
| Kadir IS et al. | Recurrent acute rheumatic fever: a forgotten diagnosis? | 2004 | Ann. Thorac. Surg. | pmid:15276555 |
| Bossert T et al. | Successful management of two heart transplant recipients with mycobacterial pulmonary infections. | 2005 | Ann. Thorac. Surg. | pmid:16039241 |
| Watanabe M et al. | Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. | 2006 | Ann. Thorac. Surg. | pmid:16731124 |
| Callaghan R and Allen M | Mycobacterium malmoense infection of the knee. | 2003 | Ann. Rheum. Dis. | pmid:14583565 |
| Rhee CS et al. | Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. | 2000 | Ann. Otol. Rhinol. Laryngol. | pmid:10823478 |
| Heffernan CB et al. | Does Clarithromycin Cause Hearing Loss? A 12-Year Review of Clarithromycin Therapy for Nontuberculous Mycobacterial Lymphadenitis in Children. | 2018 | Ann. Otol. Rhinol. Laryngol. | pmid:30032669 |
| Clifford K et al. | Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. | 1999 | Ann. Otol. Rhinol. Laryngol. | pmid:10214783 |
| Mullin D et al. | Mycobacterium chelonae infections involving the head and neck. | 2009 | Ann. Otol. Rhinol. Laryngol. | pmid:19894399 |
| Ferreri AJ et al. | High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. | 2015 | Ann. Oncol. | pmid:25935794 |
| Di Raimondo F et al. | Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? | 2007 | Ann. Oncol. | pmid:17065587 |
| Trotti LM et al. | Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial. | 2015 | Ann. Neurol. | pmid:26094838 |
| Yang YJ et al. | Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. | 2017 | Ann. Med. | pmid:28266875 |
| Musher DM | Clarithromycin therapy for Mycobacterium avium complex bacteremia. | 1995 | Ann. Intern. Med. | pmid:7778830 |
| van der Meer JT and Danner SA | Clarithromycin therapy for Mycobacterium avium complex bacteremia. | 1995 | Ann. Intern. Med. | pmid:7778831 |
| Patel AM et al. | Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. | 2013 | Ann. Intern. Med. | pmid:23778904 |
| Steinman MA et al. | Changing use of antibiotics in community-based outpatient practice, 1991-1999. | 2003 | Ann. Intern. Med. | pmid:12667022 |
| Chaisson RE et al. | Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. | 1994 | Ann. Intern. Med. | pmid:7978715 |
| Goldberger M and Masur H | Clarithromycin therapy for Mycobacterium avium complex disease in patients with AIDS: potential and problems. | 1994 | Ann. Intern. Med. | pmid:7978725 |
| Shafran SD et al. | Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. | 2002 | Ann. Intern. Med. | pmid:12416943 |
| Vaira D et al. | Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. | 2007 | Ann. Intern. Med. | pmid:17438314 |
| Singh N and Yu VL | Clarithromycin therapy for Mycobacterium avium complex bacteremia. | 1995 | Ann. Intern. Med. | pmid:7632282 |
| Neu HC | New macrolide antibiotics: azithromycin and clarithromycin. | 1992 | Ann. Intern. Med. | pmid:1310839 |
| McMahon BJ et al. | The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. | 2003 | Ann. Intern. Med. | pmid:13679322 |
| Sjölund M et al. | Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. | 2003 | Ann. Intern. Med. | pmid:13679325 |
| Summaries for patients. Past antibiotic use affects resistance and outcomes of Helicobacter pylori infection. | 2003 | Ann. Intern. Med. | pmid:13679344 | |
| Summaries for patients. Effects of antibiotic treatment for Helicobacter pylori on normal bowel bacteria. | 2003 | Ann. Intern. Med. | pmid:13679347 | |
| Liviu L et al. | Pancreatitis induced by clarithromycin. | 1996 | Ann. Intern. Med. | pmid:8849171 |
| Seow J and Chew FT | Risk factors for Helicobacter pylori resistance. | 2004 | Ann. Intern. Med. | pmid:15172911 |
| Ohkusa T et al. | Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. | 1998 | Ann. Intern. Med. | pmid:9841603 |
| Summaries for patients. Factors associated with Helicobacter pylori infections in the United States that are resistant to usual antibiotics. | 2002 | Ann. Intern. Med. | pmid:11797613 | |
| De Francesco V et al. | Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. | 2006 | Ann. Intern. Med. | pmid:16418408 |
| Meyer JM et al. | Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. | 2002 | Ann. Intern. Med. | pmid:11777360 |
| Trivedi S et al. | Clarithromycin and digoxin toxicity. | 1998 | Ann. Intern. Med. | pmid:9518419 |